Eli Lilly just raised its full-year revenue guidance by billions thanks to surging demand for Zepbound and Mounjaro, proving the weight-loss drug market is still underserved. Novo Nordisk's CEO separately confirmed that Wegovy profitability will keep impr

Verdict: Wait for RSI confirmation before entering this GLP-1 bounce

The GLP-1 demand thesis is fundamentally validated by Eli Lilly's results—44.7% revenue growth to $65.2B and 96.0% EPS growth place it in the 90th percentile for return on equity among healthcare peers—but the strategy's technical entry conditions have not triggered for either name. LLY sits 3.6 RSI points below the 35 crossover trigger at 31.4, while NVO at 20.3 RSI needs a 14.7-point recovery; both stocks trade below their 50-day EMAs and Bollinger middle bands without a confirmed MACD bullish crossover. The 60-month NVO backtest returned 89.2% with a 100% win rate on a single trade and an 18.5% maximum drawdown, but that sample is extremely thin and exit fills were assessed only on daily bars. Meanwhile, the near-zero 0.0633 LLY–NVO correlation means the risk-parity blend's expected maximum drawdown of 63.4% offers little practical downside protection when one component carries a negative skew of -1.67 and kurtosis of 12.75. NVO's gross margin compression from 84.7% to 81.0% and ROE decline from 70.4% to 52.8% add fundamental caution to an already unconfirmed technical setup. **Conviction breakdown** - **Thesis support (70):** LLY's explosive fundamentals and NVO's CEO commentary on improving Wegovy profitability strongly support the category thesis, though NVO's margin compression and ITGR's weak standalone performance temper conviction. - **Trade readiness (25):** No entry conditions are fully met; both names need RSI to cross above 35 and MACD bullish crossovers that have not occurred. - **Risk quality (45):** The 2:1 reward-to-risk framework is sound, but daily-bar exit fills are coarse, NVO's tail risk is severe, and the 63.4% expected portfolio drawdown is punishing. - **Backtest evidence (55):** The 89.2% return and 100% win rate are encouraging but rest on a single trade over 60 months—an extremely thin sample that limits statistical confidence. - **Fundamentals trend (65):** LLY's growth is exceptional, but NVO's decelerating revenue (6.4%), declining margins, and ITGR's 14.0% EPS decline create a mixed cross-sectional picture.

Trade now

**Action today: Wait.** No entry conditions are fully triggered for either Novo Nordisk (NVO) or Eli Lilly (LLY). The strategy looks for a bullish reversal setup—price below the 50-day EMA but recovering above the 20-day Bollinger Band middle, with RSI crossing above 35 and a MACD bullish crossover. Right now both stocks are deeply oversold but have not yet confirmed a turn. For NVO at $44.28, two of four conditions are already met: price is below the 50-day EMA ($47.08) and below the Bollinger middle band ($48.53). But RSI sits at 20.3—well below the 35 trigger—and the MACD has not crossed above its signal line. For LLY at $1,116, price is below the 50-day EMA ($1,133)—condition met—but still about $47 below the Bollinger middle band ($1,163), RSI is at 31.4 (needs to cross above 35), and MACD has not crossed bullish. The hard stop is at the 78.6% Fibonacci retracement, backed by a fixed 2.5% stop-loss; the take-profit targets the 127.2% Fibonacci extension or a 5% gain, giving roughly a 2:1 reward-to-risk profile. The 60-month backtest on NVO returned 89.2% on a single trade with an 18.5% drawdown—real but coarse given daily-bar exit fills. No parameter sensitivity recommendation was established. "Wait" means: set alerts for RSI crossing 35 and MACD bullish crossovers on both NVO and LLY. If either stock stabilizes and RSI begins climbing from current oversold levels, the remaining conditions could fall into place rapidly.

The GLP-1 growth engine is confirmed — and backed by the numbers

The bull case rests squarely on Eli Lilly's demonstrated ability to convert GLP-1 demand into explosive top-line growth. Per the CNBC report on the Q2 2026 print, Lilly easily topped estimates and raised its full-year outlook as Zepbound and Mounjaro sales surged. The fundamentals confirm the narrative: LLY's revenue grew 44.7% year-over-year to $65.2B, placing it in the 60th percentile for sector growth despite already being one of the largest healthcare companies in the world. Diluted EPS nearly doubled, posting 96.0% year-over-year growth to $22.95, and return on equity stands at 77.8% — the 90th percentile among 943 healthcare peers. This is not a speculative promise of future growth; it is booked, confirmed, and accelerating. Novo Nordisk validates the thesis that the entire GLP-1 category is…

Scores

• Conviction score breakdown: 52
• Thesis support: 70
• Trade readiness: 25
• Risk quality: 45
• Backtest evidence: 55
• Fundamentals trend: 65

Watch items

• LLY — RSI (14)
• NVO — RSI (14)
• LLY — Price vs Bollinger (20) middle band
• NVO — Price vs Bollinger (20) middle band
• NVO — Price vs nearest support
• LLY — Price vs nearest support
• LLY — Price below EMA (50)
• LLY — Price above Bollinger (20)
• LLY — RSI (14) crossed above 35
• LLY — MACD (12,26,9) crossed above MACD (12,26,9)